Aro Biotherapeutics, a trailblazer in the biotechnology sector based in Philadelphia, is excited to announce a significant funding milestone, having raised $41,500,000 to propel its innovative work in genetic medicines. With a dedication to unlocking the potential of genetic therapies, Aro Biotherapeutics is utilizing its proprietary protein technology, Centyrins, to pioneer a new generation of tissue-targeted genetic medicines. This transformative approach aims to optimize therapeutic delivery and effectiveness, ensuring that treatments are focused precisely where they are needed most in the body. The funds raised will be instrumental in advancing Aro's wholly-owned pipeline of Centyrin-based therapeutic candidates and expanding ongoing partnerships with industry leaders to explore the broader applications of this groundbreaking technology. The capital will support essential R&D initiatives, allowing the company to accelerate clinical trials and enhance its capabilities in targeting diseases that currently lack effective treatment options. With this funding, Aro Biotherapeutics is poised to make substantial progress in the field of genetic medicines, aligning with its vision of transforming patient outcomes through innovative, next-generation therapies. As the company forges ahead, it remains committed to a mission of improving the lives of those affected by challenging medical conditions by harnessing the power of advanced genetic science and technology.
Breaking Boundaries: Aro Biotherapeutics Secures $41.5 Million in Series B Funding to Revolutionize Genetic Medicines
Recently funded · $41.5M Series bBiotechnology
Get the full Aro Biotherapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | NEW ID | Series b | $705.2K | today |
| 2 |  Arist United States | Series b | $14.1M | today |
| 3 |
